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in patients with proximal vertebral artery stenosis
George A. Antoniou, MD, PhD,a David Murray, MD, FRCS,a George S. Georgiadis, MD,b
Stavros A. Antoniou, MD,c Andrew Schiro, MD, MRCS,a Ferdinand Serracino-Inglott, MD, FRCS,a and
J. Vincent Smyth, ChM, FRCS,a Manchester, United Kingdom; Alexandroupolis, Greece; and
Mönchengladbach, Germany
Background: Atherosclerotic occlusive disease of the proximal vertebral artery is an important cause of cerebrovascular
ischemic events with a significant associatedmorbidity andmortality. Endovascular treatment has emerged as a promising
tool of the therapeutic armamentarium, along with medical therapy and surgical reconstruction. Our objective was to
systemically review the pertinent evidence on the endovascular management of proximal vertebral artery disease and
perform an analysis of the published outcomes.
Methods: A systematic review of the literature identified all studies reporting percutaneous transluminal angioplasty or
stenting, or both, for proximal vertebral artery stenosis. Web-based search engines were searched using the Medical
Subject Headings terms “vertebral artery,” “angioplasty,” and “stents” in all possible combinations. Studies comprising
a series of at least five patients were considered for analysis. Periprocedural transient ischemic attack and stroke and death
from any cause <30 days of treatment were defined as the primary outcome end points.
Results:One randomized controlled trial comparing angioplasty and stenting of the proximal vertebral artery andmedical
therapy was identified. No comparative studies of endovascular treatment and open surgical repair were found. Forty-two
selected studies reported endovascular treatment (angioplasty or stenting, or both) of 1117 vertebral arteries in 1099
patients. The weighted mean technical success rate was 97% (range, 36%-100%). Periprocedural transient ischemic attack
occurred in 17 patients (1.5%). The combined stroke and death rate was 1.1%. Recurrent symptoms of vertebrobasilar
insufficiency developed in 65 of 967 patients (8%) within a reported follow-up of 6 to 54 months. Restenosis developed
in 183 of 789 patients (23%) who underwent follow-up imaging (range, 0%-58%). Reintervention for recurrent disease
during follow-up occurred in 86 patients (9%; range, 0%-35%).
Conclusions: There is limited comparative evidence on the efficacy of medical, surgical, and endovascular treatment of
proximal vertebral artery disease. Percutaneous transluminal angioplasty and stenting has low periprocedural neurologic
adverse events and mortality. ( J Vasc Surg 2012;55:1167-77.)
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tAtherosclerotic occlusive disease of the vertebral artery is
an insidious condition with potentially debilitating conse-
quences. The true prevalence of this condition in the general
population remains largely unknown. Large stroke registries
have shown that approximately one-quarter of cerebrovascu-
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doi:10.1016/j.jvs.2011.09.084ar ischemic events affect tissue supplied by the vertebrobasilar
irculation, and stenosis of the proximal vertebral artery may
ccount for up to 20%of these events.1-4 In contrast to carotid
tenosis, the natural history and prognosis of vertebral artery
isease have not been delineated. The mortality associated
ith a vertebrobasilar circulation stroke may be as high as
0%.5,6 Furthermore, patients experiencing vertebrobasilar
ransient ischemic attacks (TIAs) have a 25% to 35% risk of
troke within 5 years.7 Atherosclerosis most commonly affects
he origin and proximal portion of the vertebral artery and is
requently associated with similar disease in the internal ca-
otid artery.7
The optimum management of occlusive vertebral ar-
ery disease remains elusive.Medical therapy with antiplate-
et or anticoagulant agents constitutes the initial manage-
ent for stroke prevention. Although revascularization is
dvocated in patients with symptomatic stenosis refractory
o conservative management, its benefit is currently uncer-
ain. Surgery is an option in specialist centers, and satisfac-
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April 20121168 Antoniou et altory results, as expressed by stroke and death rates, have
been reported.8 Endovascular repair has emerged as a treat-
ment option; however, insufficient evidence currently exists
to support the safety and efficacy of percutaneous translu-
minal angioplasty (PTA), with or without stenting, for
vertebral artery stenosis.9 The objective of the present study
was to systemically review the pertinent evidence on the
endovascular management of proximal vertebral artery dis-
ease and perform a comprehensive analysis of the published
results.
METHODS
Eligibility criteria for study selection and patient
inclusion. A prespecified protocol of the objectives and
methods of the present systematic review was established.
Studies reporting the endovascular treatment of proximal
vertebral artery stenosis were identified. Randomized and
nonrandomized clinical trials comparing endovascular
treatment with open surgical repair and endovascular treat-
ment with best medical care and prospective and retrospec-
tive case series were considered. Studies comprising at
least five patients of any age and sex with symptomatic or
asymptomatic proximal vertebral artery atherosclerotic
disease were eligible. We reviewed articles reporting an
acceptable endovascular technique with PTA, with or with-
out stenting, or primary stenting alone. The primary out-
come measures were periprocedural TIA and stroke and
death from any cause30 days of treatment or30 days of
randomization for patients receiving medical treatment.
TIA and stroke were defined as a neurologic deficit in the
vertebrobasilar territory lasting24 hours and24 hours,
respectively.
Only articles providing details on the primary outcome
measures were enrolled and considered for further analysis.
Secondary outcome measures were subsequent vertebro-
basilar territory symptoms (TIA or stroke, or both), reste-
nosis rate (resulting from recurrent disease at the previously
treated segment of the vertebral artery documented on
follow-up imaging), reintervention rate (including inter-
vention at the restenosed segment of the vertebral artery, as
defined above), and late mortality (defined as death occur-
ring 30 days of treatment or randomization and divided
into death related and unrelated to posterior cerebral cir-
culation insufficiency).
Search strategy. Studies were identified by searching
electronic databases and scanning reference lists of articles.
Consultation with experts in the field and informal inquires
were obtained. The search was applied to MEDLINE
(database provider PubMed, from 1966 to April 2011),
EMBASE (database provider Ovid, from 1980 to April
2011), and the Cochrane Library (April 2011). Only Eng-
lish language articles were considered. The last search was
run in April 2011. The Medical Subject Headings (MeSH)
“vertebral artery,” “angioplasty,” and “stents” were used in
combination with the Boolean operators and or or. Eligi-
bility assessment was performed independently in an un-
blinded standardized manner by two reviewers. Disagree-
ments between reviewers were resolved by consensus. lData collection and analysis. A data extraction sheet
as developed, pilot tested on 10 randomly selected in-
luded studies, and refined accordingly. One review author
xtracted the data from included studies and a second
uthor checked the extracted data. Data were identified in
ublished material only, and extracted information in-
luded study design (randomized or nonrandomized, pro-
pective or retrospective), characteristics of study partici-
ants (age, sex, contralateral vertebral artery disease,
nterior circulation disease, hypertension, coronary artery
isease, diabetes mellitus, dyslipidemia), indication for
reatment, type of intervention (PTA or stenting, or both),
ite of arterial access for endovascular treatment, unilateral
r bilateral treatment, outcome measure (periprocedural
IA and stroke, 30-day mortality, length of follow-up,
umber of patients followed up, mode of follow-up, reste-
osis rate, recurrent vertebrobasilar circulation symptoms,
eintervention rate, and late mortality). For study cohorts
f endovascular treatment of vertebral artery disease, means
f outcome parameters were weighted and data were
ooled after significant outcome heterogeneity was ex-
luded. Data analysis was performed using SPSS 15 soft-
are (SPSS Inc, Chicago, Ill).
ESULTS
Literature search results. The search of the electronic
ibliographic sources identified 1369 records, and the
anual search of the reference lists of the selected articles
dded another 56 relevant citations. After excluding articles
hose titles or abstracts had no relevance to the area of
oncern of this systematic review, the full texts of 190
rticles were retrieved and assessed for eligibility. The pres-
nt review and analysis excluded articles other than original
eports, study cohorts of less than five patients, studies
eporting on endovascular treatment of the intracranial
egment of the vertebral artery, and studies containing
ixed data involving treatment of other supra-aortic
ranches or various segments of the posterior circulation.
Of the 47 articles that met the inclusion criteria,10-56 an
dditional five were excluded because of overlapping data
ublished from the same center in different periods.52-56
nly the most recent report and that containing the largest
umber of patients were considered for further analysis
Fig). No unpublished relevant studies were obtained. The
iterature review conformed to Preferred Reporting Items
or Systematic Reviews and Meta-Analyses (PRISMA)
tatement standards, a protocol for conducting systematic
eviews and meta-analyses developed by a panel of experts
n this field.57
The analysis included 40 retrospective case studies or
etrospective series with prospectively collected data. Two
dditional comparative studies (one randomized controlled
rial and one nonrandomized study) of vertebral artery
ngioplasty/stenting and medical treatment were found.
o studies comparing the outcomes after conventional
pen surgical repair of the proximal vertebral artery with
ndovascular treatment were located. Articles were pub-
ished between 1981 and 2011, and 36 of 42 included
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Volume 55, Number 4 Antoniou et al 1169articles (86%) were published between 2000 and 2011,
with four articles only having been published in the 1990s
and another two in the 1980s.
Study characteristics. The selected studies reported
the endovascular treatment (PTA or stenting, or both) of
1117 vertebral arteries in 1099 patients. The selected arti-
cles reported study groups with a mean of 26 patients
(range, 5-117 patients). The baseline demographic and
clinical characteristics of the study groups are presented in
Table I. Of the 1032 patients, 774 (75%) were men, and
the reported mean age of the selected study cohorts was
between 54 and 72 years. The presence of contralateral verte-
bral artery disease was recorded in 29 articles (69%), and 484
of the 869 patients (56%) in these studies had bilateral verte-
bral artery disease (prevalence range, 9%-100%).Disease in the
anterior cerebral circulation was recorded in 22 studies (52%)
and was present in 299 of 654, for a prevalence of 46%
(prevalence range, 0%-83%). No details were provided on the
status of the innominate or subclavian artery.
The indication for treatment varied among the studies
(Table II). Most of the authors treated vertebral artery
stenosis in patients with associated posterior circulation
symptoms refractory to conservative medical management.
The symptoms of posterior circulation insufficiency were
specified in 13 studies, and all of these patients had a
combination of persisting vertebrobasilar insufficiency
symptoms. Furthermore, most authors stated that an exam-
ination by a stroke physician was performed before and
after treatment, and a team of physicians from different
disciplines made the decision for treatment. Different ste-
Fig. Flow chart shows literaturenosis thresholds to warrant endovascular treatment were ased. Several authors treated asymptomatic stenosis in pa-
ients with significant contralateral vertebral artery disease
r disease in the anterior circulation, or both.
The approach of vascular access for vertebral artery
ntervention was documented by 22 articles (Table II). The
essel used for arterial access in 544 of 587 patients (93%)
as the femoral artery; other approaches were the transax-
llary in 0.1%, transbrachial in 2%, or transradial in 5% of
atients. PTA was the sole procedure in 84 patients (8%),
hereas 1015 (92%) underwent stenting of the proximal
ertebral artery, with or without predilation with balloon
ngioplasty. Antiproliferative drug-eluting stents were used
n 209 of the stent patients (21%).
Most authors reported administration of dual-
ntiplatelet treatment with aspirin and clopidogrel. Therapy
as commenced several days before the endovascular proce-
ure and continued for 1 to 12 months after treatment;
herapywith one antiplatelet agentwas continued indefinitely.
Synthesis of results and outcome. The main peripro-
edural and late outcome measures are outlined in Table
II. The reported technical success rate was 36% to 100%
mong the studies, with a weightedmean value of 97%. The
uthors of the selected articles used different criteria to
efine technical success, with most authors assuming that
echnical success was achieved when a 20% residual ste-
osis of the treated segment of the vertebral artery existed
t the end of the procedure. TIA and stroke, periprocedural
r within the early days after the intervention, occurred in
7 and six patients, yielding a mean value of 1.5% and 0.5%,
espectively. Six patients died 30 days of the vertebral
h strategy. VA, Vertebral artery.rtery intervention (30-day mortality rate, 0.5%). Four of
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April 20121170 Antoniou et althe six deaths were stroke related, whereas the other two
deaths were caused by a myocardial infarction. The esti-
mated combined mean stroke and death rate was 1.1%.
Follow-up outcome was reported by 37 articles, with a
mean follow-up of between 6 and 54months. Eight articles
reported a follow-up of 1 year (219 patients), 22 articles
monitored their patients for 1 to 3 years (266 patients), and
another three articles provided a follow-up 3 years (191
patients). A total of 967 patients (88% of the total review
population) were assessed with clinical examination or a
vertebral artery imaging investigation, including ultra-
sound imaging, computed tomography angiography, mag-
Table I. Baseline demographic and clinical characteristics
First author (year)
Patients Male sex Mean age
Cont
d
No. No. (%) (years) N
Chen (2011)10 47 32 (68) 60 28
Hatano (2011)11 117 94 (80) 67 53
Werner (2010)12 28 17 (61) 66 5
Parkhutik (2010)13 28 21 (75) 64 8
Park (2010)14 20 15 (75) 64 14
Zhou (2010)15 61 45 (74) 64 37
Edgell (2010)16 5 4 (80) 60 5
Ogilvy (2010)17 50 30 (60) NR 33
Karameshev (2010)18 10 8 (80) 60 8
Chung (2010)19 20 20 (100) 64 3
Yu (2009)20 10 9 (90) 66 8
Seifert (2009)21 29 23 (79) 63
Vajda (2009)22 48 36 (75) 68 24
Lin (2008)23 11 9 (82) 72 1
Taylor (2008)24 72 55 (76) 62 47
Akins (2008)25 12 NR 64
Tsutsumi (2007)26 12 8 (67) 71
Yip (2007)27 24 22 (92) 69
Kizilkilic (2007)28 12 9 (75) 65
Canyigit (2007)29 16 14 (88) 60 8
Dabus (2007)30 25 18 (72) 68 23
Lin (2006)31 80 64 (80) 72 26
Coward (2006)32 8 5 (63) 63
Qureshi (2006)33 12 9 (75) 68
Kantarci (2006)34 12 10 (83) 62 8
Eberhardt (2006)35 9 NR 65 7
Weber (2005)36 36 27 (75) 61 34
Ko (2004)37 25 16 (64) 56 6
Janssens (2004)38 16 12 (75) 54 9
Hauth (2004)39 11 7 (64) 61
Cloud (2003)40 14 9 (64) 56
Albuquerque
(2003)41
33 24 (73) 65 27
Jenkins (2001)42 32 22 (69) 67
Kogure (2001)43 19 15 (79) 67
Mukherjee (2001)44 12 10 (83) 72
Piotin (2000)45 7 6 (86) 68 7
Chastain (1999)46 50 37 (74) 63 27
Malek (1999)47 9 5 (56) 59 8
Fessler (1998)48 6 4 (67) 63 5
Higashida (1993)49 33 NR NR
Brückmann (1986)50 13 NR NR 13
Motarjeme (1981)51 5 3 (60) NR 2
CAD, Coronary artery disease; DM, diabetes mellitus; HTN, hypertension;netic resonance angiography, or conventional digital sub- rraction angiography. The types of imaging follow-up used
y the selected studies are outlined in Table III.
Recurrent symptoms of vertebrobasilar insufficiency
eveloped 65 patients (8%). During follow-up, 21 patients
ied for a mean late mortality rate of 2%, with one death
nly being reported to be associated with insufficiency of
he posterior cerebral circulation. Restenosis in the previ-
usly treated segment of the vertebral artery occurred in
83 of the 789 patients who underwent follow-up imaging,
or an accumulated restenosis rate of 23% (range, 0%-58%).
nconsistency was identified in the definition of restenosis:
he authors of 23 articles defined it as the presence of
e study groups
ral
Anterior
circulation
disease HTN CAD DM Dyslipidemia
No. (%) No. (%) No. (%) No. (%) No. (%)
8 (17) 36 (77) 3 (6) 12 (26) 5 (11)
40 (34) 85 (73) 29 (25) 53 (45) 32 (27)
17 (61) 26 (93) 14 (50) 13 (46) 17 (61)
14 (50) 17 (61) 13 (46) 11 (39) 15 (54)
6 (30) NR NR NR NR
NR 43 (70) 16 (26) 20 (33) 23 (38)
) NR 3 (60) 0 (0) 0 (0) 3 (60)
30 (60) NR NR NR NR
) NR 7 (70) 0 (0) 2 (20) 7 (70)
NR NR NR NR NR
7 (70) NR NR 3 (30) 10 (100)
NR NR NR NR NR
NR 23 (48) NR 13 (27) 13 (27)
5 (45) 10 (91) 6 (55) 3 (27) 3 (27)
NR 45 (63) 32 (44) 18 (25) 23 (32)
5 (42) 9 (75) 7 (58) 3 (25) 9 (75)
NR NR NR NR NR
8 (33) 21 (88) 20 (83) 11 (46) 14 (58)
NR NR NR NR NR
12 (75) 9 (56) 7 (44) 5 (31) 1 (6)
13 (52) 19 (76) 13 (52) 9 (36) 9 (36)
50 (63) 57 (71) 55 (69) 22 (28) 42 (53)
NR 5 (63) 2 (25) 0 (0) 5 (65)
NR 11 (92) 2 (17) 5 (42) 7 (58)
9 (75) NR NR NR NR
NR NR NR NR NR
NR NR NR NR NR
9 (36) 16 (64) 18 (72) 9 (36) 10 (40)
NR 7 (44) 2 (13) 1 (6) 15 (94)
NR NR NR NR NR
7 (50) 7 (50) 2 (14) 2 (14) 11 (79)
15 (45) NR NR NR NR
24 (75) 23 (72) 24 (75) 7 (22) 25 (78)
NR NR NR NR NR
NR 11 (92) 8 (67) 5 (42) 8 (67)
) NR NR NR NR NR
10 (20) 38 (76) 38 (76) 12 (24) 24 (48)
5 (56) 7 (78) 2 (22) 2 (22) 1 (11)
5 (83) 4 (67) 3 (50) 1 (16) NR
NR NR NR NR NR
) NR NR NR NR NR
0 (0) NR NR NR NR
ot reported.of th
ralate
isease
o. (%)
(60)
(45)
(18)
(29)
(70)
(61)
(100
(66)
(100
(15)
(80)
NR
(50)
(9)
(65)
NR
NR
NR
NR
(50)
(92)
(33)
NR
NR
(67)
(78)
(94)
(24)
(56)
NR
NR
(82)
NR
NR
NR
(100
(54)
(89)
(83)
NR
(100
(40)ecurrent stenosis 50% at the previously treated segment
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Volume 55, Number 4 Antoniou et al 1171Table II. Indication and mode of endovascular treatment of proximal vertebral artery stenosis in the study groups
First author Indication for treatment Approach PTA Stenting
Bilateral
treatment
Chen10 Symptomatic 70% stenosis NR 0 47 (DES) 2
Hatano11 Symptomatic 60% stenosis or
asymptomatic 60% stenosis with
infarction in posterior circulation
Transfemoral, 113/transbrachial, 4 0 117 No
Werner12 Symptoms refractory to medical treatment
 60% stenosis
Transfemoral, 28 0 28 (DES) No
Parkhutik13 Symptomatic 50% stenosis or
asymptomatic 50% stenosis  anterior
circulation disease
Transfemoral, 27/transbrachial, 1 0 28 1
Park14 Symptomatic stenosis or asymptomatic
stenosis  limited collateral circulation
NR 0 20 (DES) No
Zhou15 Symptomatic 50% stenosis NR 0 61 2
Edgell16 Symptomatic 50% stenosis  contralateral
VA disease
NR 0 5 (DES) No
Ogilvy17 Symptomatic 60% stenosis/asymptomatic
 70% stenosis  contalateral VA disease
NR 0 50 (DES, 15 cases) No
Karameshev18 Basilar artery thrombosis due to VA
occlusion or crescendo TIAs or
hemodynamic TIA/stroke
Transfemoral, 10 0 10 (DES, 6 cases) 1
Chung19 Symptomatic 50% stenosis or
asymptomatic 70% stenosis 
contralateral disease
NR 0 20 No
Yu20 Symptoms refractory to medical treatment
 50% stenosis (45% stenosis if
contralateral VA occlusion)
NR 0 10 (DES) No
Seifert21 Symptomatic stenosis or asymptomatic
stenosis  severe contralateral disease
NR 0 29 (DES, 3 cases) No
Vajda22 Not defined Transfemoral, 48 0 48 (DES) 4
Lin23 Symptomatic 75% stenosis with RD 3.5
mm or symptomatic 50% stenosis with
RD 3 mm
NR 0 11 (DES) No
Taylor24 Symptomatic stenosis or asymptomatic
stenosis  contralateral VA/anterior
circulation disease
NR 0 72 5
Akins25 Symptoms refractory to medical treatment
 60% stenosis
NR 0 12 (DES, 5 cases) No
Tsutsumi26 Symptomatic 70% stenosis NR 0 12 No
Yip27 Symptomatic 50% stenosis or
asymptomatic 70% stenosis
Transradial, 24 0 24 No
Kizilkilic28 Symptomatic 70% stenosis NR 0 12 2
Canyigit29 Symptomatic 50% stenosis or
asymptomatic 70% stenosis
Transfemoral, 16 0 16 2
Dabus30 Symptoms refractory to medical treatment
 50% stenosis
NR 3 22 No
Lin31 Symptomatic 75% stenosis for 3.5 mm
VA or symptomatic 50% stenosis for 3
mm VA  contralateral occlusion
Transfemoral, 80 0 80 10
Coward32 Symptomatic 50% stenosis NR 2 6 No
Qureshi33 Symptoms refractory to medical treatment
 50% stenosis
Transfemoral, 9/transradial, 3 0 12 (DES, 10 cases) No
Kantarci34 Symptoms refractory to medical treatment
 70% stenosis
Transfemoral, 12 0 12 1
Eberhardt35 Symptomatic high-grade stenosis NR 0 9 No
Weber36 Symptoms refractory to medical treatment
 70% stenosis
NR 0 36 No
Ko37 Symptomatic stenosis or asymptomatic
70% stenosis
Transfemoral, 25 0 25 (DES, 1 case) No
Janssens38 Not defined Transfemoral, 16 16 0 3
Hauth39 Not defined NR 8 3 No
Cloud40 Symptomatic 70% stenosis or symptomatic
70% stenosis  severe contralateral
disease  occluded posterior
communicating artery
Transfemoral, 12/transbrachial, 2 4 10 NoDES, Drug-eluting stent; NR, not reported; PTA, percutaneous transluminal angioplasty; RD, reference diameter; TIA, transient ischemic attack; VA,
vertebral artery.
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April 20121172 Antoniou et alof the vertebral artery. Reintervention for recurrent proxi-
mal vertebral artery disease during follow-up occurred in
86 patients, for an accumulated reintervention rate of 9%
(range, 0%-35%).
DISCUSSION
Vertebral artery stenosis is an important cause of pos-
terior circulation cerebrovascular events, with a significant
associated morbidity and mortality. In marked contrast to
atherosclerotic stenosis in the anterior circulation, occlusive
disease of the extracranial vertebral artery has received little
attention. Current evidence suggests that the risk of subse-
quent stroke or death in patients with vertebrobasilar isch-
emic events is similar to the risk in patients with carotid
territory TIAs and strokes.58 However, no clear-cut indica-
tions and management of vertebral artery disease have been
established, and the boundaries among the treatment arms
of medical therapy, surgical reconstruction, and endovas-
cular intervention have not been delineated.
Most authors converge on medical treatment with es-
tablished antiplatelet agents as the initial management of
patients with symptomatic vertebral artery disease. Revas-
cularization is advocated in patients who have symptoms
refractory to conservative management, even though its
beneficial effect on stroke reduction remains unclear. Sur-
gical options are endarterectomy, bypass, or transposition
of the vertebral artery to the common carotid artery. The
modern complication rates of surgical vertebral reconstruc-
tion are quite low in specialist centers, and good long-term
results have been reported in large series.8,59-61 A growing
published series of PTA with or without stenting of the
Table II. Continued
First author Indication for treatment
Albuquerque41 Symptoms refractory to medical treatment
or angiographic risk factors
NR
Jenkins42 Symptoms refractory to medical treatment
 70% stenosis
Tra
Kogure43 Symptoms refractory to medical treatment
 60% stenosis or asymptomatic 60%
stenosis  posterior circulation infarct
Tra
Mukherjee44 Not defined Tra
Piotin45 Symptoms refractory to medical treatment
 70% stenosis  contralateral VA
equally diseased
Tra
Chastain46 Symptomatic bilateral/unilateral dominant
 60% stenosis or asymptomatic 60%
stenosis  limited collateral circulation
Tra
Malek47 Symptomatic stenosis refractory to medical
treatment
Tra
Fessler48 Vertebrobasilar insufficiency refractory to
medical treatment
Tra
Higashida49 Symptoms refractory to medical treatment
 70% stenosis
NR
Brückmann50 Symptoms  contralateral high-grade
stenosis/occlusion
Tra
Motarjeme51 Not defined Travertebral artery origin has shown promising results. mThe present systematic review of the literature failed to
dentify any conclusive evidence for the superiority of any of
he three treatment modalities. A randomized controlled
rial evaluating PTA and stenting for symptomatic vertebral
rtery stenosis compared with medical therapy showed no
enefit of endovascular treatment: no patient in either arm
xperienced a recurrent vertebrobasilar territory stroke up
o 8 years after randomization.32 However, meaningful
nalysis of the results of this trial was limited by the small
umbers of participants enrolled (eight patients in either
roup), and the results of a larger randomized clinical trial
ssessing best medical treatment with or without stenting
or symptomatic vertebral artery stenosis are awaited.62
urthermore, there is limited comparative evidence of en-
ovascular vs surgical revascularization of the diseased
roximal vertebral artery.63
Analysis of the series included in this review showed
hat percutaneous reconstruction of the proximal vertebral
rtery is a safe and effective procedure, as demonstrated by
he low perioperative stroke and death rates. In a cohort
f 1099 patients, six sustained a periprocedural posterior
irculation-related stroke, and another six died30 days of
ntervention. Distal protection devices to prevent cerebro-
ascular events during wire/catheter manipulation and
tent placement were used in25 cases. In view of the low
rocedural risks, the effect of these devices on stroke reduc-
ion is difficult to evaluate, whereas most authors would not
dvocate their use for this vessel size. Furthermore, high
echnical success rates have been reported in percutaneous
econstruction of the extracranial vertebral artery, with
Approach PTA Stenting
Bilateral
treatment
0 33 No
oral, 31/transbrachial, 1 0 32 6
oral, 19 0 19 1
oral, 12 0 12 No
oral, 6/transbrachial, 4 0 7 No
oral, 49/transbrachial, 1 0 50 5
oral, 9 0 9 No
oral, 4/transradial, 2 0 6 No
33 0 1
oral, 13/transaxillary, 1 13 0 No
oral, 5 5 0 Nonsfem
nsfem
nsfem
nsfem
nsfem
nsfem
nsfem
nsfemost studies achieving a residual stenosis of 20%.
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Volume 55, Number 4 Antoniou et al 1173Table III. Early and late outcome after angioplasty/stenting of proximal vertebral artery stenosis
First author
Technical
success rate, % TIA Stroke
30-day
mortality
Mean
follow-up
Follow-up
patients
Mode of
follow-up
imaging
Restenosis
rate on
follow-up
Recurrent
symptoms Reintervention
Death on
follow-up
(definition) No. No. No. (months) (No.) (definition) No. (%) No. (%) No.
Chen10 100 (20%
RS)
0 0 0 28 47 DSA in
38
5%
(moderate
stenosis)
3 (6) 0 (0) 2
Hatano11 99 (30%
RS)
2 0 0 48 104 DSA 12%
(50%
stenosis)
5 (5) 9 (9) NR
Werner12 100 (20%
RS)
0 0 0 16 28 DSA 21%
(50%
stenosis)
6 (21) 0 (0) 0
Parkhutik13 100 (ND) 1 0 0 32 28 US
(MRA/
DSA in
19)
4% (50%
stenosis)
1 (4) 0 (0) 0
Park14 100 (ND) 0 0 0 15 20 DSA 25%
(50%
stenosis)
2 (10) 4 (20) 0
Zhou15 100 (30%
RS)
0 1 0 13 61 DSA 31%
(50%
stenosis)
3 (5) 5 (8) 0
Edgell16 100 (ND) 0 0 0 15 5 DSA/
CTA
0% (50%
stenosis)
1 (20) 0 (0) 0
Ogilvy17 100 (successful
stent
deployment)
0 0 0 NR 44 CTA in
36
31%
(50%
stenosis)
0 (0) 7 (16) 0
Karameshev18 100 (20%
RS/no
adverse
events)
1 0 0 25 10 US 10%
(50%
stenosis)
1 (10) 1 (10) 0
Chung19 95 (no
significant
RS)
0 0 0 15 19 US 0% (50%
stenosis)
0 (0) 0 (0) 0
Yu20 80 (20%
RS)
0 0 0 12 10 DSA 0% (50%
stenosis)
0 (0) 0 (0) 0
Seifert21 NR 0 1 0 24 29 US 52%
(50%
stenosis)
2 (7) 4 (14) 3
Vajda22 100 (ND) 0 0 0 8 48 DSA 13%
(50%
stenosis)
0 (0) NR 0
Lin23 100 (20%
RS)
0 0 0 19 11 DSA in 2 0% (50%
stenosis)
0 (0) 0 (0) 0
Taylor24 100 (ND) 1 2 1 9 66 DSA in
44
58%
(50%
stenosis)
9 (14) 23 (35) 2
Akins25 NR 0 0 0 30 12 US/CT 25%
(50%
stenosis)
2 (17) 3 (25) 2
Tsutsumi26 100 (30%
RS)
0 0 0 32 12 DSA/US 8% (70%
stenosis)
0 (0) 1 (8) 0
Yip27 100 (ND) 1 0 0 NR NR NR NR NR NR NR
Kizilkilic28 NR 0 0 0 NR NR NR NR NR NR NR
Canyigit29 100 (ND) 0 0 0 NR NR NR NR NR NR NR
Dabus30 92 (20%
RS)
0 0 2 24 19 None NA 5 (26) 3 (16) 0
Lin31 100 (20%
RS)
0 3 0 38 79 US (DSA
in 40)
28%
(50%
stenosis)
1 (1) 1 (1) 1
Coward32 100 (successful
stent
deployment)
2 0 0 54 8 US 43%
(50%
stenosis)
2 (25) 1 (13) 2
CTA, Computed tomography angiography; DSA, digital subtraction angiography; MRA, magnetic resonance angiography; NA, not applicable ND, not
defined; NR, not reported; RS, residual stenosis; TIA, transient ischemic attack; US, ultrasound imaging.
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concerns about a high incidence of restenosis and reinter-
vention, and the benefit of interventional endovascular
treatment has not been proven. An early report comparing
the long-term outcome of vertebral artery origin angio-
plasty and primary stenting demonstrated significantly re-
duced restenosis rates with the latter treatment.40 Resteno-
sis of the previously treated vertebral artery developed in
Table III. Continued
First author
Technical
success rate, % TIA Stroke
30-day
mortality
Mean
follow-up
F
(definition) No. No. No. (months)
Qureshi33 100 (30%
RS)
0 0 0 NR
Kantarci34 100 (ND) 1 0 0 23
Eberhardt35 NR 0 0 0 23
Weber36 100 (20%
RS)
1 0 0 11
Ko37 100 (20%
RS)
0 0 0 25
Janssens38 47 (20%
RS)
0 0 0 30
Hauth39 36 (20%
RS)
0 0 0 NR
Cloud40 71 (20%
RS)
1 0 0 NR
Albuquerque41 100 (ND) 0 1 1 16
Jenkins42 100 (20%
RS)
1 0 0 11
Kogure43 100 (ND) 0 2 0 11
Mukherjee44 100 (50%
RS/decrease
in stenosis
20)
0 0 0 6
Piotin45 100 (20%
RS)
0 0 0 15
Chastain46 98 (50%
RS)
0 1 1 25
Malek47 100 (20%
RS)
1 0 0 23
Fessler48 NR 1 0 0 8,4
Higashida49 100 (30%
RS)
3 0 0 NR
Brückmann50 93 (ND) 0 0 1 15
Motarjeme51 80 (ND) 0 0 0 NR23% of patients who underwent imaging follow-up. Fur- shermore, 86 of 183 patients (47%) found to have resteno-
is on follow-up imaging underwent reintervention for
ymptomatic recurrent disease. This fact underlines the
ot-so-insignificant rate of recurrent symptoms after endo-
uminal therapy. Restenosis rates among different series are
ifficult to compare due to the different endovascular treat-
ents (angioplasty vs stenting), different stents used for the
ndovascular reconstruction (bare-metal vs drug-eluting
-up
nts
Mode of
follow-up
imaging
Restenosis
rate on
follow-up
Recurrent
symptoms Reintervention
Death on
follow-up
.) (definition) No. (%) No. (%) No.
NR NR NR NR NR
DSA/US 33%
(50%
stenosis)
1 (8) 1 (8) 0
US 50%
(mild/
moderate
stenosis)
0 (0) 0 (0) 0
DSA 46% (not
defined)
1 (4) 5 (19) 0
DSA in
13
31%
(50%
stenosis)
2 (9) 0 (0) 1
US/
MRA
16%
(50%
stenosis)
1 (6) 0 (0) 1
NR NR NR NR NR
DSA in
4,
US in
10
36%
(50%
stenosis)
1 (7) 1 (7) 4
DSA 43%
(50%
stenosis)
3 (10) 11 (37) 1
None NA 1 (3) 1 (3) 0
DSA in
14
43% (
half of
initial
gain)
0 (0) NR 0
None NA 0 (0) 1 (8) 0
US 0% (ND) 1 (14) 0 (0) 0
DSA in
44
11%
(50%
stenosis)
2 (4) 1 (2) 1
None NR 5 (56) NR 0
DSA in
4
0% (ND) 0 (0) 0 (0) 0
US/
MRA/
DSA
9% (ND) 0 (0) 2 (6) 1
US 17% (ND) 4 (33) 1 (8) 0
None NA 0 (0) 0 (0) 0ollow
patie
(No
NR
12
4
26
22
16
NR
14
30
32
19
12
7
49
9
6
33
12tents), the differing methods used to image the extracra-
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stenoses, and the different follow-up periods.
In an attempt to inhibit the neointimal hyperplasia
associated with in-stent restenosis, several authors have
proposed the chemotherapeutic effect of drug-eluting
stents. Seven of the selected articles used drug-eluting
stents for their entire study population (169 pa-
tients).10,12,14,16,20,22,23 Of these, 151 patients underwent
imaging follow-up with digital subtraction angiography,
eight of whom (12%) developed restenosis during a mean
follow-up of between 7 and 28 months (restenosis range,
0%-25%). No comparative studies evaluating the potential
beneficial effects of drug-eluting stents on patency rates
have been identified.
Vertebral artery angioplasty and stenting is a technical
demanding endovascular procedure, which should be per-
formed in specialist centers. Cannulation of the vertebral
arteries can be very challenging, and the imaging is often
very difficult due to the inherent tortuosity and posterior
course of even a normal proximal vertebral artery segment.
Frequently, multiple views are required to adequately visu-
alize the vertebral origin, and maintaining catheter posi-
tion, particularly on the right, can be problematic. Many
of the studies selected for this review have limited postop-
erative imaging or even clinical follow-up only.
Angiograms obtained with computed tomography an-
giography and magnetic resonance angiography do not
provide adequate imaging of the proximal vertebral artery,
and once a stent is in place, causing artifact, these imaging
studies would have limited usefulness. The gold standard
for imaging the proximal vertebral artery remains digital
subtraction angiography. However, a well-performed du-
plex ultrasound study may provide an informative follow-
up, even though a new set of poststent velocity criteria
similar to carotid and mesenteric stents may need to be
established.
The reviewed literature has several weaknesses and
inherent biases, which should be taken into account before
interpreting the results and reaching conclusions. Themain
limitation of the present review is the poor quality of the
studies included in the analysis. It is likely that in the
absence of a registry, the literature may only be reporting
those patients with a good outcome, and there will be an
obvious publication bias to only publish small series with
good results. The various authors used different criteria for
selecting patients for endovascular treatment, which would
potentially affect the outcome end points set for the pur-
poses of this review. Half of the patients had bilateral
disease, which implies (at least in part) that half of the
patients who underwent interventions had a normal con-
tralateral vertebral artery. Recalling that the paired arteries
join to become the basilar artery should make one question
the indications for intervention in these patients, because it
is unlikely that half of the cohort have embolizing lesions.
Furthermore, significant heterogeneity existed in the
clinical characteristics of the study populations, whereas the
prevalence of contralateral vertebral and anterior circula-
tion disease differed considerably among the studies. Dif-erent treatments (angioplasty/primary stenting, use of
rug-eluting stents) would have significant outcome ef-
ects, and many authors included mixed data and made no
istinction between the specific procedure-related out-
omes.
ONCLUSIONS
There is limited comparative evidence on the safety and
fficacy of medical, surgical, and endovascular treatment of
roximal vertebral artery disease. PTA and stenting has
volved as a safe minimally invasive therapeutic method,
ssociated with low periprocedural neurologic adverse
vents and death. There seems to be a significant restenosis
ate associated with angioplasty and primary stenting,
hich has, however, an asymptomatic course and leads to a
ower reintervention rate. Further randomized trials com-
aring stenting with medical therapy are required, and the
ole of novel therapeutic modalities with the use of drug-
luting stents in the long-term efficacy of the endovascular
reatment needs to be separately evaluated.
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